Avadel Pharmaceuticals Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy AVDL

*Your capital is at risk

$21.64

+0 (+0%)

At Close: May 08, 2026

Avadel Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -99.62. In total, the insiders bought 265.03K and sold 17.96M AVDL shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-99.62
● Buy	265.03K shares
● Sell	17.96M shares
20% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Feb 12, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -99.62. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (20% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Feb 11, 2026 Buy	Ordinary Shares	Weiss Asset Management Lp 10 Percent Owner	10% Owner	0 Value: $0
Feb 04, 2026 Sell	Ordinary Shares G-Gift	Mccamish Mark Anthony Director	Director	67 025 Value: $0
Feb 04, 2026 Buy	Ordinary Shares G-Gift	Mccamish Mark Anthony Director	Director	67 025 Value: $1.45M
Sep 15, 2025 Sell	Stock Option (Right to Buy) G-Gift	Palczuk Linda Director	Director	11 000 Value: $119.1K
Sep 15, 2025 Sell	Stock Option (Right to Buy) G-Gift	Glass Geoffrey Michael Director	Director	11 000 Value: $119.1K
Sep 15, 2025 Sell	Stock Option (Right to Buy) G-Gift	Glass Geoffrey Michael Director	Director	11 000 Value: $119.1K
Sep 15, 2025 Sell	Stock Option (Right to Buy) G-Gift	Palczuk Linda Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Mccamish Mark Anthony Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Mccamish Mark Anthony Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Palczuk Linda Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Palczuk Linda Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Thornton Peter J. Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Thornton Peter J. Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Glass Geoffrey Michael Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Amin Naseem Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Amin Naseem Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Ende Eric J Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Ende Eric J Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Glass Geoffrey Michael Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Glass Geoffrey Michael Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Thornton Peter J. Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Thornton Peter J. Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Palczuk Linda Director	Director	11 000 Value: $119.1K
Jul 29, 2025 Buy	Ordinary Shares A-Award	Palczuk Linda Director	Director	11 000 Value: $116.9K
Jul 29, 2025 Buy	Stock Option (Right to Buy) A-Award	Mccamish Mark Anthony Director	Director	11 000 Value: $119.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT AVADEL PHARMACEUTICALS PLC

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorpo...

Read Full Profile Here